AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26787629 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 71
Study 26031308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium HandiHaler®
Number of subjects: 0
Study 26031308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24093855 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cardiology follow-up after AMI
Number of subjects: 533
Study 24093855 — intervention group
Group type: COMPARATOR
Intervention: Uninsured status
Number of subjects: 533
Study 24093855 — intervention group
Group type: COMPARATOR
Intervention: Cardiologist-driven inpatient medical decision making
Number of subjects: 533
Study 24093855 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall LVEF reassessment
Number of subjects: 533
Study 24093855 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 533
Study 22143216 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual Care Education Program (SCEP), 2 hours per week for 6 weeks
Number of subjects: 81
Study 22143216 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 81
Study 19258472 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal BMI (18.5-25)
Number of subjects: 28380
Study 19258472 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight BMI (25-30)
Number of subjects: 28380
Study 19258472 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese BMI (30-35)
Number of subjects: 28380
Study 19258472 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidly Obese BMI (>35)
Number of subjects: 28380
Study 19258472 — intervention group
Group type: EXPERIMENTAL
Intervention: All BMI categories
Number of subjects: 28380
Study 16925685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a cumulative dose of around 41824 IR, equivalent to 1.7 mg of D.p. and 3.0 mg of D.f. allergen for 6 months.
Number of subjects: 20
Study 16925685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 20
Study 16925685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15541243 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of left ventricular sphericity
Number of subjects: 825
Study 15541243 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of 10-year survival rate
Number of subjects: 825
Study 12805106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 23
Study 12805106 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 23
Study 12805106 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 23
Study 12805106 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 23
Study 9593493 — intervention group
Group type: EXPERIMENTAL
Intervention: SDR plus physical therapy (PT)
Number of subjects: 43
Study 9593493 — intervention group
Group type: COMPARATOR
Intervention: PT alone
Number of subjects: 43
Study 9593493 — intervention group
Group type: EXPERIMENTAL
Intervention: SDR plus PT
Number of subjects: 43
Study 8537612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime and ceftriaxone
Number of subjects: 20
Study 2244793 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride maintained at an average dose of 200 mg
Number of subjects: 128
Study 2244793 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly interpersonal psychotherapy
Number of subjects: 128
Study 489751 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelling and feedback from the supervisor (MF)
Number of subjects: 24
Study 489751 — intervention group
Group type: COMPARATOR
Intervention: Feedback from the supervisor (F)
Number of subjects: 24
Study 489751 — intervention group
Group type: COMPARATOR
Intervention: No modelling, no feedback (NMF)
Number of subjects: 24
Study 31821664 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder-umbilical length measurement (experimental group)
Number of subjects: 110
Study 31821664 — intervention group
Group type: COMPARATOR
Intervention: Birthweight measurement (control group)
Number of subjects: 110
Study 31161812 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 74
Study 31161812 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 74
Study 28079828 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV primary vaccination and booster dose
Number of subjects: 283
Study 28079828 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 283
Study 26027627 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T
Number of subjects: 5385
Study 26027627 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 5385
Study 26027627 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth differentiation factor 15 (GDF-15)
Number of subjects: 5385
Study 26027627 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 5385
Study 26027627 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 5385
Study 22774850 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal conditions with fast presentation rate
Number of subjects: 0
Study 22774850 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal conditions with medium presentation rate
Number of subjects: 0
Study 22774850 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal conditions with slow presentation rate
Number of subjects: 0
Study 22774850 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory suppression (AS)
Number of subjects: 0
Study 22774850 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal prevented (slower rates)
Number of subjects: 0
Study 22774850 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt rehearsal methodology
Number of subjects: 0
Study 22774850 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal encoding conditions
Number of subjects: 0
Study 21415072 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 2426
Study 21415072 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 2426
Study 21415072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2426
Study 19157352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway (PLA)
Number of subjects: 90
Study 19157352 — intervention group
Group type: COMPARATOR
Intervention: Classic Laryngeal Mask Airway (LMA)
Number of subjects: 90
Study 17915636 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine immediate release tablet formulation 1
Number of subjects: 18
Study 17915636 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine immediate release tablet formulation 2
Number of subjects: 18
Study 17915636 — intervention group
Group type: COMPARATOR
Intervention: In vitro dissolution testing
Number of subjects: 18
Study 15334791 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (3+/−1 mg/d)
Number of subjects: 164
Study 15334791 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2500+/−500 mg/d)
Number of subjects: 164
Study 15334791 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride and Metformin
Number of subjects: 164
Study 15334791 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 164
Study 11953015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine-mobilized autologous cancer donors
Number of subjects: 62
Study 11953015 — intervention group
Group type: COMPARATOR
Intervention: Cytokine-mobilized normal allogeneic stem-cell donors
Number of subjects: 62
Study 11953015 — intervention group
Group type: COMPARATOR
Intervention: Untreated volunteers
Number of subjects: 62
Study 9924263 — intervention group
Group type: EXPERIMENTAL
Intervention: Detarium flour in stew meal
Number of subjects: 15
Study 9924263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus flour in bread meal
Number of subjects: 15
Study 9924263 — intervention group
Group type: EXPERIMENTAL
Intervention: Detarium bread meal
Number of subjects: 15
Study 9924263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus bread meal
Number of subjects: 15
Study 9924263 — intervention group
Group type: COMPARATOR
Intervention: Fibre-rich stew meal
Number of subjects: 15
Study 30340481 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education and Preventive Equipment Package (HEPEP)
Number of subjects: 645
Study 30340481 — intervention group
Group type: COMPARATOR
Intervention: Control group (five-minute lecture)
Number of subjects: 645
Study 28270389 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE-D web-based tool
Number of subjects: 71
Study 28270389 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 26615342 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 100
Study 26615342 — intervention group
Group type: COMPARATOR
Intervention: Control (no zinc supplementation)
Number of subjects: 100
Study 23635945 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoaraiosis presence and severity assessed via brain MRI (T2, FLAIR)
Number of subjects: 183
Study 23635945 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 183
Study 23635945 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 183
Study 23635945 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) severity measured by oxygen desaturation index (ODI)
Number of subjects: 183
Study 19864905 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 2% w/w CPP
Number of subjects: 150
Study 19864905 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1,190 mg/kg fluoride as 0.76% SMFP
Number of subjects: 150
Study 19864905 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste without CPP or fluoride
Number of subjects: 150
Study 17534206 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted acetabular component insertion (CAOS+ group)
Number of subjects: 60
Study 17534206 — intervention group
Group type: COMPARATOR
Intervention: Free hand placement (CAOS- group)
Number of subjects: 60
Study 15155420 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS administration for 8 or 14 weeks
Number of subjects: 35
Study 15155420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (200 mg/week) for 8 weeks
Number of subjects: 35
Study 15155420 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 35
Study 11772827 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% isobaric
Number of subjects: 80
Study 11772827 — intervention group
Group type: COMPARATOR
Intervention: Racemic bupivacaine 0.5% isobaric
Number of subjects: 80
Study 11477839 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus concentrated Xuefu Zhuyu Pill (CXZP)
Number of subjects: 84
Study 11477839 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 84
Study 7642849 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 170
Study 7642849 — intervention group
Group type: COMPARATOR
Intervention: Coronary angioplasty
Number of subjects: 170
Study 2665351 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV vaccine (new inactivated rabies vaccine grown on Vero cells)
Number of subjects: 144
Study 2665351 — intervention group
Group type: COMPARATOR
Intervention: HDCV vaccine (rabies vaccine cultivated on human diploid cells)
Number of subjects: 144
Study 30598 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.5 mg)
Number of subjects: 31
Study 30598 — intervention group
Group type: EXPERIMENTAL
Intervention: Meprobamate (200 mg)
Number of subjects: 31
Study 30598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30598 — intervention group
Group type: EXPERIMENTAL
Intervention: Kymographic recordings
Number of subjects: 31
Study 31777188 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (measured by Five Facet Mindfulness Questionnaire)
Number of subjects: 177
Study 31328807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine hemisulfate sustained-release tablets 5 mg
Number of subjects: 12
Study 31328807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine hemisulfate sustained-release tablets 10 mg
Number of subjects: 12
Study 31328807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine hemisulfate sustained-release tablets 15 mg
Number of subjects: 12
Study 31328807 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyl ivabradine 5 mg
Number of subjects: 12
Study 31328807 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyl ivabradine 10 mg
Number of subjects: 12
Study 31328807 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyl ivabradine 15 mg
Number of subjects: 12
Study 28962727 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-thread TADs
Number of subjects: 30
Study 28962727 — intervention group
Group type: COMPARATOR
Intervention: Dual-thread TADs
Number of subjects: 30
Study 25437153 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient affective processing (RAP) intervention (n = 12)
Number of subjects: 33
Study 25437153 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition (n = 11)
Number of subjects: 33
Study 25437153 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP intervention (n = 12)
Number of subjects: 33
Study 23657918 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus fluoropyrimidines (FL)
Number of subjects: 0
Study 23657918 — intervention group
Group type: COMPARATOR
Intervention: FL only
Number of subjects: 0
Study 21966834 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0
Study 21966834 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 0
Study 19453814 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 38
Study 19453814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 17314694 — intervention group
Group type: EXPERIMENTAL
Intervention: Open incubator (n = 23)
Number of subjects: 42
Study 17314694 — intervention group
Group type: COMPARATOR
Intervention: Warming bassinet (n = 19)
Number of subjects: 42
Study 15646226 — intervention group
Group type: EXPERIMENTAL
Intervention: TM-primer applied and dried according to manufacturer's directions
Number of subjects: 12
Study 15646226 — intervention group
Group type: EXPERIMENTAL
Intervention: T30-primer allowed to dry for an additional 30 seconds
Number of subjects: 12
Study 15646226 — intervention group
Group type: EXPERIMENTAL
Intervention: T60-primer dried for an additional 60 seconds
Number of subjects: 12
Study 15646226 — intervention group
Group type: EXPERIMENTAL
Intervention: T120-primer dried for an additional 120 seconds
Number of subjects: 12
Study 11361192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2,400 mg/day
Number of subjects: 182
Study 11361192 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 4,000 mg/day
Number of subjects: 182
Study 11361192 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 1,200 mg/day
Number of subjects: 182
Study 9743780 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual 1-hour tutorial session on MEDLINE use
Number of subjects: 0
Study 9743780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7803332 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15‐0.20 mg/kg)
Number of subjects: 145
Study 7803332 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (4‐6 mg/kg)
Number of subjects: 145
Study 7803332 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 145
Study 7803332 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 145
Study 2460500 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott enzyme immunoassay for HIV antigen
Number of subjects: 0
Study 2460500 — intervention group
Group type: COMPARATOR
Intervention: Reverse transcriptase assay (RTA)
Number of subjects: 0
Study 31097309 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL device (lens awareness logger)
Number of subjects: 40
Study 27768546 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (10 weeks of supervised moderate intensity exercise at 50% of heart rate reserve)
Number of subjects: 104
Study 25858333 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 798
Study 25858333 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 798
Study 25858333 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 798
Study 23918455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal pulmonary surfactant (PS)
Number of subjects: 0
Study 23918455 — intervention group
Group type: COMPARATOR
Intervention: Saline treatment
Number of subjects: 0
Study 23918455 — intervention group
Group type: COMPARATOR
Intervention: Untreated OME
Number of subjects: 0
Study 23918455 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 21403524 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (50 mg/day)
Number of subjects: 20
Study 21403524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21403524 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 20
Study 18829151 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MHz frequency or 1 watt/cm(2) power continuous ultrasound for 5 min, 10 sessions
Number of subjects: 67
Study 18829151 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (placebo)
Number of subjects: 67
Study 18179001 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 70% isopropyl alcohol
Number of subjects: 57
Study 18179001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg granisetron IV
Number of subjects: 57
Study 18179001 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment control
Number of subjects: 57
Study 15337551 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 284
Study 15337551 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 284
Study 11135716 — intervention group
Group type: COMPARATOR
Intervention: Infusion of saline for 12 h (Group A: 169 patients)
Number of subjects: 510
Study 11135716 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of tranexamic acid, 1 mg x kg(‐1) x h(‐1) for 12 h (Group B: 171 patients)
Number of subjects: 510
Study 11135716 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of tranexamic acid, 2 mg x kg(‐1) x h(‐1) for 12 h (Group C: 170 patients)
Number of subjects: 510
Study 9821028 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of two capsules of Cyclo 3 Fort in the morning
Number of subjects: 37
Study 9821028 — intervention group
Group type: COMPARATOR
Intervention: Twice daily dose of one capsule of Cyclo 3 Fort morning and noon
Number of subjects: 37
Study 7978434 — intervention group
Group type: COMPARATOR
Intervention: Placebo PO + tetracaine 12 mg IT
Number of subjects: 40
Study 7978434 — intervention group
Group type: COMPARATOR
Intervention: Placebo PO + tetracaine 12 mg IT + fentanyl 10 micrograms IT
Number of subjects: 40
Study 7978434 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 200 micrograms PO + tetracaine 12 mg IT
Number of subjects: 40
Study 7978434 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 200 micrograms PO + tetracaine 12 mg IT + fentanyl 10 micrograms IT
Number of subjects: 40
Study 2800973 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 40
Study 2800973 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 40
Study 1065740 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial mouthwash containing cetylpyridinium chloride and domiphen bromide
Number of subjects: 120
Study 1065740 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial mouthwash containing only cetylpyridinium chloride
Number of subjects: 120
Study 1065740 — intervention group
Group type: COMPARATOR
Intervention: Colored flavored water (Control)
Number of subjects: 120
Study 29202277 — intervention group
Group type: COMPARATOR
Intervention: Clobazam (0.25, 0.50, or 1.0 mg/kg/d) during lead-in; Clobazam up to 2.0 mg/kg/d (maximum 80 mg/d) during OLE
Number of subjects: 0
Study 29202277 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam dosage increase of ≥ 20% during long-term treatment
Number of subjects: 0
Study 26633145 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube (ETT) with premedication (atropine and morphine)
Number of subjects: 60
Study 26633145 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA) with premedication (atropine only)
Number of subjects: 60
Study 26633145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ETT and LMA)
Number of subjects: 60
Study 25047862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 2162
Study 25047862 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 2162
Study 25047862 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 2162
Study 25047862 — intervention group
Group type: COMPARATOR
Intervention: Anti-platelet agents
Number of subjects: 2162
Study 25047862 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 2162
Study 22506793 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-School Success (FSS)
Number of subjects: 199
Study 22506793 — intervention group
Group type: COMPARATOR
Intervention: Coping With ADHD Through Relationships and Education (CARE)
Number of subjects: 199
Study 20422948 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule formulation
Number of subjects: 32
Study 18043456 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day therapy with amoxicillin-clavulanate
Number of subjects: 39
Study 18043456 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day therapy with amoxicillin-clavulanate
Number of subjects: 39